{"anticipatedPostingDate":"2027-11","denomUnitsSelected":"Participants","description":"To assess the safety and tolerability of the selumetinib granule formulation.","reportingStatus":"NOT_POSTED","timeFrame":"from screening until 30 days after last dose","title":"Adverse Events Graded by CTCAE Ver 5.0","type":"PRIMARY"}